Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 60Neoplasms 41Carcinoma, Non-Small-Cell Lung 32Ovarian Neoplasms 27Neoplasm Metastasis 22Glioblastoma 19Lung Neoplasms 17Fallopian Tube Neoplasms 16Colonic Neoplasms 16Breast Neoplasms 16Rectal Neoplasms 15Pancreatic Neoplasms 15Carcinoma, Renal Cell 13Carcinoma, Hepatocellular 12Stomach Neoplasms 10Glioma 10Carcinoma, Ovarian Epithelial 8Solid Cancers 7Sarcoma 7Melanoma 7Liver Neoplasms 7Brain Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Solid Tumors 6Uterine Cervical Neoplasms 5Recurrence 5Lymphoma, Non-Hodgkin 5Astrocytoma 5Advanced Cancer 5Triple Negative Breast Neoplasms 4

Interventions

Gemcitabine 11Cisplatin 9Oxaliplatin 7Leucovorin 6Irinotecan 6Fluorouracil 5Taxes 3Radiotherapy 3Platinum 3Interleukin-12 Subunit p35 3Erlotinib Hydrochloride 3Capecitabine 3Albumin-Bound Paclitaxel 31,2-diaminocyclohexaneplatinum II citrate 3Trastuzumab 2Docetaxel 2Carboplatin 2130-nm albumin-bound paclitaxel 2tipifarnib 1sargramostim 1pembrolizumab 1motexafin gadolinium 1merestinib 1guadecitabine 1entinostat 1durvalumab 1dehydroftorafur 1aldesleukin 1Thalidomide 1Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gallbladder Neoplasms × Bevacizumab × Clear all
NCT04164069 2024-12-27

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
9 enrolled
Gastrointestinal

Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡